Johnson & Johnson announced on Tuesday that it had submitted data to the United States Medicines Agency (FDA) for authorization of a recall in adults.

Its Janssen vaccine against Covid-19 initially works with a single dose.

These data include the results of a clinical study that showed a second dose injected approximately two months (56 days) after the first showed 94% efficacy against symptomatic (moderate to severe) cases in the United States.

The effectiveness is even 100% against severe cases 14 days after this second injection, indicates the pharmaceutical group in a press release.

In turn, @JNJNews filed a @US_FDA file to authorize a booster dose of its # COVID19 vaccine in adults, 2 months after the first injection (decision expected this month) https://t.co/cOcsISk5iUhttps: //t.co/nsB2MzSrO9

- Covidix Coro (@covidix) October 6, 2021

Urgently authorized in February 2021

A second dose also increases the levels of antibodies against the coronavirus observed nine-fold, according to another Johnson & Johnson study, and twelve-fold four weeks after the booster.

The vaccine, in single dose or booster dose, is generally well tolerated by patients, assures the American company.

The FDA said its expert panel will meet on Oct. 14 and 15 to review clearance applications from Johnson & Johnson and the Moderna company.

The Janssen single-dose vaccine has benefited from emergency authorization in the United States since February 2021 and has been administered to 15 million people, far fewer than the Pfizer (229.3 million) and Moderna (152 million) vaccines.

The question of the third dose

The United States has already authorized a third dose of the Pfizer vaccine for people 65 years of age and over, as well as some at "risk" because of their state of health or because of a job particularly exposing them to the virus.

People who are immunocompromised may also get a booster dose of Moderna's vaccine.

The subject of the third dose, at the center of the new American vaccine strategy launched in September, has revived the issue of inequalities between rich and poor countries.

Access to the first dose of vaccine remains very limited in some regions of the world, particularly in Africa.

Did you see ?

Covid-19: Americans marry at the border with Quebec to reunite their families

World

Coronavirus in Cuba: High school students returned to school after nine months of closure

  • Health

  • World

  • Vaccination

  • Vaccine

  • United States

  • Coronavirus

  • Covid 19

  • Janssen